ArticleThe Journal of biological chemistry2026
RNF90 promotes hepatic steatosis by degrading CPT1α to suppress fatty acid oxidation.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic fatty acid oxidation (FAO) is crucial for maintaining hepatic lipid homeostasis, and dysregulation of hepatic lipid metabolism is closely associated with metabolic dysfunction-associated fatty liver disease. However, the molecular mechanisms governing FAO in hepatocytes remain incompletely understood. Here, we demonstrate that RNF90 is essential for FAO regulation, with its expression significantly upregulated in fatty liver. Further investigation revealed that RNF90 is transcriptionally activated by KLF5 and functions as an E3 ubiquitin ligase to promote the ubiquitin-dependent proteasomal degradation of carnitine palmitoyltransferase 1α (CPT1α), a rate-limiting enzyme in mitochondrial FAO. Hepatocyte-specific RNF90 knockout significantly increased CPT1α protein expression, enhanced FAO activity, and alleviated hepatic steatosis, as evidenced by reduced hepatic lipid accumulation and triglyceride levels. Conversely, overexpression of wildtype RNF90 (but not its E3 ligase-deficient mutant) exerted the opposite effects. Function rescue experiments further confirm that CPT1α is indispensable for RNF90-mediated regulation of FAO and protection against hepatic steatosis. Collectively, our study establishes RNF90 as a critical regulator of hepatic lipid metabolism and identifies the KLF5/RNF90/CPT1α axis as a potential therapeutic target for metabolic dysfunction-associated fatty liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.